Table 2.

Approved anti-obesity drugs acting in the central nervous system

Drug name	Approved	Wt. loss - placebo	Common AE	Concerning AE
Phentermine et al.	1959 −1960	0.23 kg/week above placebo	Stimulation	HTN
Topiramate/phentermine	2012	6.6 kg (7.5/46mg/d)	Paresthesia	Cleft lip/palate
Lorcaserin	2012	4%	Headache	Heart valvulopathy
Bupropion/naltrexone (BN)	2014	4.8 kg (BN 360/32/d)	Nausea	HTN
Liraglutide	2014	5.6%	Nausea	Pancreatitis
Lorcaserin-ER	2016	4%	Headache	Heart valvulopathy
Drugs in Phase III
Tesofensine	NA	2% −10.6% /4.7bpm - 8.5bpm (.25-lmg/d)	Dry mouth	HTN/pulse rate

HTN = Hypertension; ER = Extended Release; BN = Bupropion/Naltrexone